The healthcare company presented new data on its kidney disease diagnostic test at a major medical conference, highlighting its ability to enhance risk assessment and guide treatment.
The healthcare company is expanding its kidney disease testing program to underserved communities in the New York metropolitan area, enabling access for over 2,000 patients.
The healthcare technology company has reported a change in shareholding, with UBS Group AG's investment bank and wealth management divisions reducing their stake in the firm.
The healthcare company has announced a change in its shareholder structure.
The healthcare company has received a notification that a major shareholder's holding has fallen below the reporting threshold.
The healthcare company announces its KidneyIntelX platform will be used in a clinical trial for a new chronic kidney disease therapy, marking a key milestone.
The healthcare company has announced a change in its shareholder structure.
The healthcare company has announced a change in its major shareholder's holdings.
The healthcare company has received a notification of a change in shareholding.
The healthcare technology company reports a change in shareholding, with a major investor reducing its stake below the 5% reporting threshold.